# First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

> **NCT03681951** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 8 (actual)

## Conditions studied

- Neoplasms, Pancreatic

## Interventions

- **DRUG:** GSK3145095
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03681951
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-16
- **Primary completion:** 2019-08-13
- **Final completion:** 2019-08-13
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study was terminated following an internal review of the company's current research and development portfolio.
- **Last updated:** 2020-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03681951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03681951, "First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03681951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*